Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Plain-language summary
This trial is testing stem cell transplant for patients with adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL), or T-cell prolymphocytic leukemia who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Must have responded to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Ruxolitinib (DRUG): Administered orally twice daily | Positron emission tomography-computed tomography (PROCEDURE): Undergo PET-CT Scan | Bone Marrow Biopsy (PROCEDURE): Undergo bone marrow biopsy | Biopsy Procedure (PROCEDURE): Undergo tissue biopsy | Biospecimen Collection (PROCEDURE): Undergo blood sample collection
Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy, Biopsy Procedure, Biospecimen Collection
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details